In current study, we aimed to investigate the prognosis of ER+/HER2+ breast cancer patients treated with trastuzumab compared with ER+/HER2- patients, thus to guide us to select appropriate endocrine treatment decision making. This evidence concerns the gene ESR1 and breast cancer.